

# Silencing of adaptor protein SH3BP2 reduces KIT/PDGFR $\alpha$ receptors expression and impairs gastrointestinal stromal tumors growth

Eva Serrano-Candelas<sup>1,2</sup>, Erola Ainsua-Enrich<sup>1,2</sup>, Arnau Navinés-Ferrer<sup>1,2</sup>, Paulo Rodrigues<sup>3</sup>, Alfonso García-Valverde<sup>4</sup>, Sarah Bazzocco<sup>3</sup>, Irati Macaya<sup>3</sup>, Joaquín Arribas<sup>4,5,6,7</sup>, César Serrano<sup>4,8</sup>, Joan Sayós<sup>9</sup>, Diego Arango<sup>3</sup> and Margarita Martín<sup>1,2</sup>

1 Biochemistry Unit, Biomedicine Department, Faculty of Medicine, University of Barcelona, Spain

2 Laboratory of Clinic and Experimental Immunology, IDIBAPS, Barcelona, Spain

3 Group of Biomedical Research in Digestive Tract Tumors, CIBBIM-Nanomedicine, Vall d'Hebron University Hospital, Research Institute (VHIR), Autonomous University of Barcelona, Spain

4 Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

5 The Catalan Institute of Research and Advanced Studies (ICREA), Barcelona, Spain

6 CIBERONC, Barcelona, Spain

7 Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Bellaterra, Spain

8 Vall d'Hebron University Hospital, Barcelona, Spain

9 Immune Regulation and Immunotherapy Group, CIBBIM-Nanomedicine, Vall d'Hebron University Hospital, Research Institute (VHIR), Autonomous University of Barcelona, Spain

## Keywords

apoptosis; gastrointestinal stromal tumors; KIT; PDGFRA; SH3BP2

## Correspondence

M. Martín, Biochemistry Unit, Biomedicine Department, Faculty of Medicine, University of Barcelona, Carrer de Casanova 143, E-08036 Barcelona, Spain  
Fax: +34 93 4035882  
Tel: +34 93 4024541  
E-mail: martin\_andorra@ub.edu

(Received 5 April 2018, revised 18 May 2018, accepted 28 May 2018, available online 30 June 2018)

doi:10.1002/1878-0261.12332

Gastrointestinal stromal tumors (GISTs) represent about 80% of the mesenchymal neoplasms of the gastrointestinal tract. Most GISTs contain oncogenic KIT (85%) or PDGFRA (5%) receptors. The kinase inhibitor imatinib mesylate is the preferential treatment for these tumors; however, the development of drug resistance has highlighted the need for novel therapeutic strategies. Recently, we reported that the adaptor molecule SH3 Binding Protein 2 (SH3BP2) regulates KIT expression and signaling in human mast cells. Our current study shows that SH3BP2 is expressed in primary tumors and cell lines from GIST patients and that SH3BP2 silencing leads to a downregulation of oncogenic KIT and PDGFRA expression and an increase in apoptosis in imatinib-sensitive and imatinib-resistant GIST cells. The microphthalmia-associated transcription factor (MITF), involved in KIT expression in mast cells and melanocytes, is expressed in GISTs. Interestingly, MITF is reduced after SH3BP2 silencing. Importantly, reconstitution of both SH3BP2 and MITF restores cell viability. Furthermore, SH3BP2 silencing significantly reduces cell migration and tumor growth of imatinib-sensitive and imatinib-resistant cells *in vivo*. Altogether, SH3BP2 regulates KIT and PDGFRA expression and cell viability, indicating a role as a potential target in imatinib-sensitive and imatinib-resistant GISTs.

## Abbreviations

GFP, green fluorescent protein; GIST, gastrointestinal stromal tumors; MC, mast cell; MITF, microphthalmia-associated transcription factor; NT, nontarget; PDGFRA, platelet-derived growth factor receptor alpha; PH, Pleckstrin homology; PLC $\gamma$ , phospholipase C gamma; SH3BP2, SH3-binding protein 2; shRNA, short hairpin RNA; TKI, tyrosine kinase inhibitor; WT, wild-type.

## 1. Introduction

Gastrointestinal stromal tumors (GIST) arise from transformed progenitor cells committed to differentiation along the interstitial cell of Cajal lineage and are the most common mesenchymal tumors of the gastrointestinal tract (Fletcher *et al.*, 2002). GISTs are characterized by activating mutations in *KIT* and *PDGFRA* genes which are shown to be mutually exclusive (Gasparotto *et al.*, 2008). *KIT* is structurally similar to platelet-derived growth factor receptor alpha (PDGFRA) and belongs to the type III receptor tyrosine kinase family (Rosnet *et al.*, 1991; Yarden *et al.*, 1987).

Between 65% and 85% of GISTs have *KIT* mutations (Heinrich *et al.*, 2003a; Miettinen *et al.*, 2005; Rubin *et al.*, 2001), while *PDGFRA* mutations are found in 5–10%. Approximately 10–15% of GISTs do not have detectable mutations in either of these receptors, suggesting that other molecules and pathways may be involved in the pathology (Lasota and Miettinen, 2008; Reichardt *et al.*, 2009; Tornillo, 2014). Most *KIT* mutations affect the juxtamembrane domain (exon 11) involved in *KIT*'s autoregulatory function and promote spontaneous kinase activation (Chan *et al.*, 2003). Exon 9 (extracellular domain) mutations are the next most common mutations, followed by exon 13 (tyrosine kinase 1 domain) and exon 17 (tyrosine kinase 2 domain) mutations. Interestingly, *PDGFRA* gain-of-function mutations are found in around half of the GISTs lacking *KIT* mutations (Heinrich *et al.*, 2003a; Hirota *et al.*, 2003). The majority of *PDGFRA* mutations affect the tyrosine kinase 2 domain (exon 18). These mutations change the activation loop, which regulates the ATP-binding pocket and leads to kinase activation (Rubin *et al.*, 2007).

Imatinib mesylate, a small molecule tyrosine kinase inhibitor (TKI), is approved for first-line treatment of metastatic and unresectable GISTs. It works by binding to the ATP-binding sites of *KIT*, *PDGFRA*, and BCR-ABL fusion product, consequently inhibiting their activity (Lyseng-Williamson and Jarvis, 2001). During imatinib treatment, resistance often develops as a result of secondary mutations, primarily in the kinase domains of *KIT* or *PDGFRA* (Chen *et al.*, 2004; McLean *et al.*, 2005; Tamborini *et al.*, 2004). Sunitinib malate, an oral multitargeted inhibitor of *KIT*, *PDGFRA*, and vascular endothelial growth factor receptor (VEGFR), is approved for the treatment of imatinib-resistant GISTs. Regorafenib is used as a third-line agent (Serrano *et al.*, 2017). However, despite an initial response to these targeted agents, tumors invariably become resistant (Kang *et al.*, 2013)

and new therapeutic approaches are needed to improve the clinical management of GIST patients.

We have recently shown that the adaptor molecule SH3-binding protein 2 (SH3BP2) regulates the expression and signaling of *KIT* receptor in human mast cells. SH3BP2 is a cytoplasmic adaptor originally identified as a protein interacting with the SH3 domain of the protein kinase ABL (Ren *et al.*, 1993). Human SH3BP2 is a 561-aa protein containing an N-terminal pleckstrin homology (PH) domain, an SH3-binding proline-rich region, and a C-terminal SH2 domain; it is preferentially expressed in hematopoietic tissues and has a regulatory role in adaptive and innate immune responses (Ainsua-Enrich *et al.*, 2012; Deckert *et al.*, 1998; Foucalt *et al.*, 2005; Jevremovic *et al.*, 2001).

Silencing of SH3BP2 downregulates *KIT* expression at transcriptional level, regulating microphthalmia-associated transcription factor (MITF) at post-transcriptional level and leading to an increase of apoptosis in human mast cells. Moreover, SH3BP2 regulates wild-type *KIT* and mutated D816V *KIT* expression (Ainsua-Enrich *et al.*, 2015), a hallmark mutation in mastocytosis, which is a rare disease comprising MC leukemia characterized by aberrant growth and accumulation of clonal MCs in different organs (Metcalf and Messori, 2017).

Here, we present the first report of the expression of SH3BP2 in primary tumors and cell lines from GIST patients. We identify its role in cell viability and tumor growth of imatinib-sensitive and imatinib-resistant GIST cells *in vitro* and *in vivo*, and provide some insights into its mechanism of action.

## 2. Materials and methods

### 2.1. Antibodies and reagents

Mouse anti-SH3BP2 (clone C5 for western blot and C11 for immunofluorescence), mouse anti-*KIT* (clone Ab81) for western blot, mouse anti-PLC $\gamma$ , rabbit anti-*KIT* (clone H300) for immunofluorescence, and rabbit anti-*PDGFRA* (clone C20) for immunofluorescence were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Rabbit anti-pPLC $\gamma$  (Y783), anti-AKT, anti-pAKT 1/2/3S473 (clon193H12), anti-pKIT (Y703) (clone D12E12), anti-*PDGFRA* (polyclonal) for western blot, and anti-MITF (clone D5G7V) were obtained from Cell Signaling Technology, Inc. (Danvers, MA, USA). Mouse anti- $\alpha$ -tubulin (clone DM1A) and anti- $\beta$ -actin (clone AC-40) were purchased from Sigma (St. Louis, MO, USA). Mouse antiphosphotyrosine (pTyr; clone PY20) was obtained from Zymed Laboratories (Invitrogen Life Technologies, Carlsbad, CA, USA). Anti-mouse and anti-rabbit IgG peroxidase

Abs were purchased from DAKO (Carpinteria, CA, USA) and Bio-Rad (Hercules, CA, USA), respectively. Imatinib and bortezomib were purchased from Sigma.

## 2.2. Cell culture

Human GIST cell lines GIST882, GIST48, and GIST48B were kindly provided by S. Bauer. GIST882 (Tuveson *et al.*, 2001) were maintained in RPMI 1640 (Lonza, Basel, Switzerland) supplemented with 15% fetal bovine serum (FBS) (Attendbio; Barcelona, Spain), 1% L-glutamine (Lonza), 50 units·mL<sup>-1</sup> penicillin, and streptomycin (Lonza). GIST48 (Bauer *et al.*, 2006) and GIST48B (Muhlenberg *et al.*, 2009) were maintained in Ham's F-10 (Lonza) supplemented with 15% FBS, 1% L-glutamine, 50 units·mL<sup>-1</sup> penicillin and streptomycin, 30 mg·mL<sup>-1</sup> bovine pituitary extract, and 0.5% MITO+ Serum Extender (Fischer Scientific, Pittsburg, PA). GIST430/654 (Bauer *et al.*, 2006) were cultured in IMDM supplemented with 15% FBS, 1% L-glutamine, 50 units·mL<sup>-1</sup> penicillin and streptomycin, and additional 200 nM imatinib mesylate (Sigma-Aldrich) to maintain selective pressure. Imatinib-sensitive GIST-T1 and imatinib-resistant GIST-T1-derived sublines GIST-T1/670 and GIST-T1/816 have been published previously (Garner *et al.*, 2014). Mycoplasma test is performed routinely in all cell lines used.

## 2.3. Immunoprecipitation and immunoblotting

Immunoprecipitation and immunoblottings with the indicated antibodies were carried out as previously described (Alvarez-Errico *et al.*, 2011). Frozen tumor samples were diced in ice-cold lysis buffer (1% NP-40, 50 mM Tris/HCl, pH 8.0, 100 mM sodium fluoride, 30 mM sodium pyrophosphate, 2 mM sodium molybdate, 5 mM EDTA, 2 mM sodium orthovanadate) on dry ice and homogenized on ice with a Tissue Tearor Homogenizer. Cell lysates were then rocked overnight at 4 °C. Lysates were cleared by centrifugation at 12 000 rpm for 30 min at 4 °C, and lysate protein concentrations were determined using a Bio-Rad protein assay. Electrophoresis and protein blotting were performed using standard techniques. Hybridization signals were detected by chemiluminescence (Immobilon Western, Millipore Corporation, Billerica, MA, USA) and captured using a G:BOX chemiluminescence imaging system (Syngene, Cambridge, UK).

## 2.4. Immunofluorescence

Immunofluorescence was performed as described elsewhere (Ainsua-Enrich *et al.*, 2012). Briefly, cells were

seeded in poly-lysine coverslips for each point 1 day before the experiment in complete media. After fixation with PFA 4%, cells were then permeabilized with saponin 0.05%, washed, and blocked before incubation with specific antibodies. Cells were incubated for 5 min with Hoechst 33258 (Bio-Rad) and mounted in Fluoromount Gold (Life Technologies). Cells were visualized with a Leica TCS SP5 confocal microscope.

## 2.5. Lentiviral transduction


Lentiviral particles to silence the SH3BP2 gene expression were generated using Mission<sup>®</sup> shRNA technology according to manufacturer's instructions (Sigma). Nontarget sequence was as follows: 5'CCGGCAACAA GATGAAGAGCACCAACTCGAGTTGGTGCTCTT CATCTTGTTGTTTT 3'. The SH3BP2-specific shRNA sequences were as follows: sequence 21:5'CC GGGCGAAGTGGAAAGGTTGTTCACTCGAGTG ACAACCTTTCCACTTCGCTTTTTG3'; sequence 17:5'CCGGGCACCCAATTATGCAAGCATTCTC GAGAATGCTTGCATAATTGGGTGCTTTTTG3'. SH3BP2-GFP and MITF-GFP were from OriGene Technologies, Rockville, MD. Lentiviral transduction for NT (nontarget), SH3BP2 silencing and GFP, SH3BP2-GFP, or MITF-GFP overexpression was performed as described in Ainsua-Enrich *et al.* (2012, 2015) with slight modifications. Virus preparations were done by precipitating viruses with polyethylene glycol (PEG) as described in Marino *et al.* (2003). GIST cells were transduced in the presence of 8 µg·mL<sup>-1</sup> of polybrene (Santa Cruz), and puromycin selection was carried out after 1 day from transduction.

## 2.6. RNA extraction, retrotranscription, and real-time PCR

One microgram of total RNA was used for cDNA retrotranscription and posterior real-time PCR for *KIT*, *PDGFRA*, and *MITF* expression analysis, following the protocol described elsewhere (Ainsua-Enrich *et al.*, 2012).

## 2.7. Cell viability and detection of caspase 3 and caspase 7 activities

Cell viability and caspase activity were assayed using the CellTiter-Glo<sup>®</sup> Luminescent Cell Viability Assay and Caspase-Glo<sup>™</sup> 3/7 Assay (Promega, San Luis Obispo, CA, USA), respectively, according to the manufacturer's instructions.



**Fig. 1.** SH3BP2 and MITF are expressed in primary tumors from GIST patients. Whole cell lysates from primary tumors with different genomic alterations as indicated in the figure and GIST T1 cell line (as control) were analyzed for pKIT, SH3BP2, and MITF expression.  $\beta$ -actin was used as loading control.

## 2.8. Wound-healing assay

Cells were cultured in 6-well plates and allowed to grow to 90% confluence. The cell monolayer was scratched with a sterile micropipette tip, and the wound region was allowed to heal by cell migration. The area that remained clear of cells after 0, 12, and 24 hours was quantified with ImageJ (National Institutes of Health, NIH) and compared with the area of the wound at time zero. Experiments were run three times in triplicate.

## 2.9. *In vivo* xenografts

For GIST882 xenograft experiments, seven-week-old female athymic nude-foxn1 mice (Envigo; Huntingdon, UK) were injected subcutaneously in both flanks with  $10^7$  GIST882 cells in complete medium. GIST430/654 xenografts were prepared by subcutaneously injecting  $5 \times 10^6$  cells in 50  $\mu$ L serum-free medium mixed with 50  $\mu$ L Matrigel ( $\sim 10$  mg $\cdot$ mL $^{-1}$ , BD Biosciences) into both flanks of six- to eleven-week-old female BALB/c severe combined immunodeficient (SCID) mice (Envigo; Huntingdon, UK). In both cases, NT shRNA control cells were injected in the left flank and SH3BP2 shRNA cells were injected in the right flank. Tumor volume ( $V$ ) was calculated with the formula:  $V = (L \times W^2) \times 0.52$ , where  $L$  is the length and  $W$  is the width of the tumor.


## 2.10. Statistical data analysis

All results are expressed as mean  $\pm$  standard error of the mean (SEM). After determination of normal distribution of the samples and variance analysis, unpaired Student's  $t$ -test was used to determine significant differences ( $P$  value) between two experimental groups and one-way ANOVA test was used to determine significant differences ( $P$  value) between several experimental groups.


## 2.11. Study approval

Animal protocol procedure was approved by Vall d'Hebron Ethical Committee for Animal Experimentation and for CEA-Generalitat de Catalunya (Catalonian Government Ethical Committee) (protocol 5769). The procedure meets local and national legislation, which is a transposition of the 2010 63 EU directive. Mice were maintained at the Vall d'Hebrón animal facility in accordance with Institutional guidelines. The samples used in the current study were provided by Tumor Bank of the Vall d'Hebron University Hospital Biobank with appropriate ethical approval. This study was approved by the Institutional Review Board from Vall d'Hebron University Hospital. Informed consent was obtained from all patients prior to study enrollment.

**Fig. 2.** SH3BP2 silencing causes a decrease in KIT and PDGFRA expression and cell viability. GIST882 and GIST48 cells were transduced with either control NT (Nontarget) shRNA or two different sequences for SH3BP2 shRNA. (A) Lysates from transduced cells were analyzed for SH3BP2, KIT, and PDGFRA protein levels. Tubulin was used as loading control. (B) Real-time PCR was performed from total mRNA using specific probes against *KIT* and *PDGFRA*. Statistical significance (\* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\*\* $P < 0.0001$ ; unpaired  $t$ -test;  $n = 3$ ; mean  $\pm$  SEM) is relative to NT shRNA. (C) Viability and caspase 3/7 activity analysis was performed in NT and SH3BP2-silenced cells. Statistical significance (\*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ ; one-way ANOVA with Bonferroni's post hoc test;  $n = 3$ ) is relative to NT shRNA.







**Fig. 3.** Microphthalmia-associated transcription factor expression is reduced in SH3BP2-silenced cells. SH3BP2 or MITF reconstitution restores cell survival. (A) GIST882 and GIST48 cells were transduced with either control NT (Nontarget) shRNA or SH3BP2 shRNA. Cell lysates were analyzed for MITF protein levels. Tubulin was used as loading control. (B) Real-time PCR was performed using specific probes against MITF. Statistical significance (\*\* $P < 0.01$ ; unpaired  $t$ -test;  $n = 3$ ; mean  $\pm$  SEM) is relative to NT shRNA. (C–F) GIST48 cells transduced with either control NT (nontarget) shRNA or SH3BP2 shRNA were posteriorly reconstituted with GFP, SH3BP2-GFP, or MITF-GFP. Evaluation of caspase 3/7 activity was performed for SH3BP2 reconstitution (C) or MITF reconstitution (D). Statistical significance (\* $P < 0.05$ , \*\*\*\* $P < 0.0001$ ; unpaired  $t$ -test;  $n = 3$ ; mean  $\pm$  SEM) is relative to GFP-transduced cells in each case. KIT surface expression by flow cytometry was assayed in SH3BP2-reconstituted (E) and MITF-reconstituted (F) SH3BP2-silenced cells. Percentage of KIT expression and mean fluorescence, in parentheses, are indicated in the FACS histograms.

### 3. Results

#### 3.1. SH3BP2 is expressed in primary tumors from GIST patients

Recently, we showed that SH3BP2 regulates KIT-D816V, a gain-of-function mutation receptor associated with mastocytosis (Ainsua-Enrich *et al.*, 2015). Microphthalmia-associated transcription factor (MITF), involved in KIT expression and signaling (Lee *et al.*, 2011; Tsujimura *et al.*, 1996), has been proposed as the target of SH3BP2 mechanism of action in mast cells (Ainsua-Enrich *et al.*, 2015). MITF has been described as an oncogene in melanoma (Garraway *et al.*, 2005), but it has not been previously studied or reported in GISTs. Active KIT mutations other than KITD816V are generally found in gastrointestinal stromal tumors (GISTs), and so the purpose of this study was to analyze the role of SH3BP2 in other KIT oncogenic mutations associated with pathology.

We first assessed the expression of SH3BP2 and MITF in primary tumors of GIST patients with a clinically representative mutation spectrum of the disease: *KIT* mutations in exon 11 and *PDGFRA* mutations in exon 18, as well as *KIT*/*PDGFRA* wild-type (WT). The presence of *KIT* mutations in exons 9, 11, 13, and 17, and *PDGFRA* mutations in exons 12 and 18 were assessed in FFPE samples from LTR cases as previously reported (Heinrich *et al.*, 2003b; Kinoshita *et al.*, 2004). As can be seen in Figure 1, SH3BP2 was present in variable amounts in all tumors with *KIT* or *PDGFRA* mutations. Interestingly, it was not detected in the GIST WT. In contrast, MITF was detected in all tumors tested.

To study SH3BP2 function, we characterized three different cell lines derived from GIST patients: GIST882 (*KIT* exon 13 K642E), an imatinib-sensitive cell line; GIST48 (*KIT* exon 11 D820A plus *KIT* exon 17 V560D), an imatinib-resistant cell line; and GIST48B, a subline of GIST48, which, despite retaining the activating *KIT* mutation, expresses *KIT* transcript and protein at essentially undetectable levels (Muhlenberg *et al.*, 2009). All GIST cell lines tested express SH3BP2 independently of their sensitivity to imatinib. Due to the

gain-of-function mutation of *KIT*, we found the receptor to be phosphorylated. *PDGFRA* was found to be phosphorylated in GIST882 and GIST48B cells, suggesting activation of this receptor in basal conditions (Fig. S1). Interestingly, SH3BP2 showed a partial colocalization with *KIT* and *PDGFRA* (Fig. S2), suggesting that it may form part of the same signalosome complex.

#### 3.2. SH3BP2 silencing correlates with *KIT* and *PDGFRA* expression and GIST cell viability

To investigate the role of SH3BP2 in GISTs, SH3BP2 gene expression was stably silenced by lentivirus-mediated shRNA in GIST882 and GIST48 cell lines. SH3BP2 knockdown was effective at this timing with two different shRNA (shRNA-21 and shRNA-17; Fig. 2A). SH3BP2 silencing was accompanied by a significant reduction in *KIT* expression at the protein (Fig. 2A) and mRNA levels (Fig. 2B) in both GIST cell lines. Interestingly, although *PDGFRA* is not expressed at protein levels in GIST48, it can be detected at mRNA levels. Notably, it was also reduced after SH3BP2 silencing in GIST48 cells (Figure 2A). These results indicate that SH3BP2 may act as a common regulator for the expression of *KIT* and *PDGFRA* receptors at transcriptional level.

We next investigated the effect of SH3BP2 silencing on cell survival. We found that the SH3BP2 knockdown reduces cell viability and increases caspase 3/7 activity (Fig. 2C), in agreement with the reduction of the expression of *KIT* and/or *PDGFRA* oncogenic receptors.

We further analyzed the effect of SH3BP2 silencing in *KIT*/*PDGFRA*-dependent signaling, evaluating the phosphorylation of PLC gamma ( $PLC\gamma$ ) and AKT that have been shown to be downstream of *KIT*/*PDGFRA* in GISTs (Bauer *et al.*, 2007; Duensing *et al.*, 2004). In GIST 882 and 48, we found a reduction in  $PLC\gamma$  phosphorylation, consistent with the positive role of this adaptor in  $PLC\gamma$  activation in mast cells reported previously by our group (Ainsua-Enrich *et al.*, 2012). AKT phosphorylation, a surrogate marker of PI3K, was also reduced consistent with the reduction in cell viability (Fig. S3).

### 3.3. The microphthalmia-associated transcription factor is reduced after SH3BP2 silencing in GIST cells

As previously reported, SH3BP2 silencing downregulates the basic helix-loop-helix transcription factor microphthalmia-associated transcription factor (MITF) expression in mast cells (Ainsua-Enrich *et al.*, 2015). MITF binds to a CACCTG motif in the *KIT* promoter and has been shown to regulate *KIT* expression in mast cells (Tsujimura *et al.*, 1996). The role of MITF in GIST remains elusive so next we assessed whether MITF was involved in SH3BP2 modulation of *KIT* expression and cell survival in GIST. As shown in Fig. 3A, the MITF protein is reduced after SH3BP2 silencing, while MITF mRNA was not altered (Fig. 3B), indicating a post-transcriptional mechanism in the SH3BP2-mediated regulation of MITF expression.


### 3.4. SH3BP2 and MITF are directly involved in cell viability in GIST cells

To analyze the specificity of the effect of SH3BP2 on cell survival, SH3BP2-silenced GIST48 cells were reconstituted with GFP-tagged SH3BP2, or with GFP as a control. For this purpose, after two days of SH3BP2 shRNA or NT transduction, when cells were

still viable, they were transduced with SH3BP2-GFP or GFP lentivirus. Six days after the last transduction and caspase activity was measured. Our data show that SH3BP2 reconstitution significantly reverses the apoptotic phenotype (Fig. 3C). The same approach was applied to assess the effect of MITF on SH3BP2-silenced cells, by reconstitution with MITF-GFP following the above procedure. Our results show that overexpression of MITF (Fig. 3D) significantly reverses the phenotype produced by SH3BP2 silencing, suggesting the involvement of this transcription factor in the regulatory mechanism in which SH3BP2 expression is critical. Efficiency and specificity of reconstitution were analyzed in all cases (Fig. S4).


### 3.5. Imatinib and bortezomib alter *KIT*, SH3BP2, and MITF expression

Next, we tested the effect of *KIT* activity inhibition as well as *KIT* expression inhibition, on SH3BP2 and MITF expression. For this purpose, we incubated GIST882 cells with imatinib and bortezomib. Incubation of GIST882 with these drugs leads to a reduction in *KIT*, SH3BP2, and MITF protein levels (Fig. S5), suggesting that these proteins are commonly affected after *KIT* expression and activity inhibition.



**Fig. 4.** SH3BP2 silencing decreases PDGFRA expression and cell survival in GIST 48B cells. (A) GIST48B cells were transduced with either control NT (Nontarget) shRNA or two different sequences of SH3BP2 shRNA. Samples were analyzed for SH3BP2 and PDGFRA protein levels. Tubulin was used as loading control. (B) Viability and caspase 3/7 activity analysis was performed in NT and SH3BP2 GIST48B-silenced cells. Statistical significance ( $***P < 0.001$ ,  $****P < 0.0001$ ; one-way ANOVA with Bonferroni's post hoc test;  $n = 3$ ; mean  $\pm$  SEM) is relative to NT shRNA. (C) NT and SH3BP2 GIST 48B-silenced cells were posteriorly transduced with GFP or SH3BP2-GFP, and caspase 3/7 activity was evaluated. Statistical significance ( $****P < 0.0001$ ; unpaired *t*-test;  $n = 3$ ; mean  $\pm$  SEM) is relative to GFP-transduced cells in each case.





**Fig. 5.** Silencing of SH3BP2 impairs cell motility/migration of GIST cells. (A) Wound-healing assay was used to assess the effect on cell migration after SH3BP2 silencing in GIST48 and GIST48B cells. The pictures show a representative experiment for each condition at different points. (B) Quantification of migrated cells is represented at different points. Statistical significance ( $***P < 0.001$ ,  $****P < 0.0001$ ; unpaired *t*-test;  $n = 3$ ; mean  $\pm$  SEM) is relative to NT shRNA.

### 3.6. SH3BP2 silencing also promotes PDGFRA downregulation and cell viability impairment in the GIST48B cell line

We have shown that SH3BP2 downregulation regulates the viability of GIST cells with activating KIT mutations that are sensitive (GIST882) and resistant (GIST48) to imatinib treatment. To investigate the effects on KIT-negative GIST cells, we used a GIST48-derivative line (GIST48B) with undetectable KIT expression due to continuous exposure to the HSP90 inhibitor 17-AAG (Muhlenberg *et al.*, 2009). Our data show that SH3BP2 silencing downregulates PDGFRA expression in GIST48B cells (Fig. 4A) in a similar fashion as in GIST882 cells. In this case, SH3BP2 knockdown also affects cell viability and increases cell apoptosis measured by caspase 3/7 activity (Fig. 4B). Consequently, SH3BP2 reconstitution significantly reduces the apoptosis resulting from SH3BP2 knockdown (Fig. 4C).


### 3.7. Cell migration is impaired after SH3BP2 silencing in GIST cells

A role for SH3BP2 has been reported in cell migration in neutrophils, through Vav and Rac2 GTPase activity (Chen *et al.*, 2012). Therefore, we next evaluated the effect of SH3BP2 silencing on the ability of cells to

migrate performing a wound-healing assay. GIST48B cells, although they do not express KIT, also migrate similar to GIST48. Our data show that SH3BP2-silenced GIST48 and GIST48B cells exhibit a significant decrease in migration, after 24 h of culture (Fig. 5). Altogether, our results indicate that SH3BP2 is important for both survival and motility in GIST cells. We also intended to perform the same approach with GIST882 cells; however, the proliferation rate of these cells was higher than their migration rate, so it was not possible to evaluate the effect of SH3BP2 on GIST882 migration (data not shown).

### 3.8. SH3BP2 silencing prevents tumor growth *in vivo*

We next tested the ability of SH3BP2 silencing to prevent GIST tumor growth in a xenograft model. To do so, GIST882 cells were transduced with NT shRNA or SH3BP2 shRNA and, after puromycin selection for two days, cells were subcutaneously injected in both flanks of athymic nude mice. NT shRNA control cells were injected in the left flank and SH3BP2 shRNA cells in the right flank. SH3BP2 protein levels were evaluated at the time of the injection (Fig. 6A). Consistent with the results obtained *in vitro*, a significant delay in tumor growth (Fig. 6B) and tumor volume



**Fig. 6.** Silencing of SH3BP2 causes a reduction in GIST tumor growth. (A) GIST882 cells were transduced with either control NT (nontarget) shRNA or SH3BP2 shRNA, and the efficiency of SH3BP2 silencing was assessed by western blot the day of the injection. Tubulin was used as loading control. (B) Bars show the day of detection of tumor in NT or SH3BP2-silenced cells. Statistical significance (\*\* $P < 0.01$ ; unpaired  $t$ -test;  $n = 4$  each experimental group; mean  $\pm$  SEM) is relative to NT shRNA. (C) Diagram shows the rate of tumor growth of NT and SH3BP2-silenced xenografts. Statistical significance (\*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ ; one-way ANOVA with Bonferroni's post hoc test;  $n = 4$  each experimental group; mean  $\pm$  SEM) is relative to NT shRNA at each time point. (D) GIST430/654 cells transduced with either control NT (nontarget) shRNA or SH3BP2 shRNA, and the efficiency of SH3BP2 silencing was evaluated by western blot the day of the injection. Tubulin was used as loading control. (E) Bars represent the percentage of viable cells after 7 days of SH3BP2 silencing *in vitro*. Statistical significance (\*\* $P < 0.01$ ; unpaired  $t$ -test;  $n = 3$ ; mean  $\pm$  SEM) is relative to NT shRNA. (F) Bars represent tumor volume of NT and SH3BP2-silenced xenografts at day 80 postinjection, and table shows tumor development in the different animals. Statistical significance (\*\* $P < 0.01$ ; unpaired  $t$ -test;  $n = 3$  each experimental group; mean  $\pm$  SEM) is relative to NT shRNA.

(Fig. 6C) was observed for the SH3BP2 shRNA cells compared to the NT shRNA control cells.

We also analyzed the *in vivo* effect of SH3BP2 silencing in the imatinib-resistant GIST48 cell line. To do so, we injected control NT and SH3BP2 shRNA-transduced GIST48 cells in mice as described above for the GIST882 cells. However, these cells failed to form

subcutaneous tumors under these conditions. After three months, no tumor growth was observed in any condition. We then evaluated the expression of SH3BP2 and MITF in other GIST cell lines, including imatinib-sensitive GIST-T1 and different imatinib-resistant sublines derived from GIST-T1 and GIST430/654 cells. Figure S6 shows that SH3BP2 and MITF

molecules are expressed in all the GIST cell lines tested.

The imatinib-resistant GIST cell line GIST430/654 (*KIT* exon 11 delV560-L576) with a secondary *KIT* mutation (*KIT* exon 13 V654) and similar kinetics to GIST882 to induce tumors (Smyth *et al.*, 2012) was used as an imatinib-resistant model for tumor growth *in vivo*. Silencing of SH3BP2 on GIST430/654 shows a reduction in *KIT* expression (Fig. 6D) and a concomitant reduction of cell viability (Fig. 6E) in accordance with the previous results. NT shRNA cells and SH3BP2 shRNA-silenced cells were injected as described above in BALB/c severe combined immunodeficient (SCID) mice. Interestingly, SH3BP2 shRNA-silenced cells did not grow in any of the animals (Fig. 6F). These *in vivo* results support the critical role of SH3BP2 in cell survival in an imatinib-resistant GIST cell line harboring different *KIT* mutations.

#### 4. Discussion

Although GISTs can be successfully treated with imatinib mesylate or other TKIs, new therapeutic options are needed because complete responses are rare and most patients develop resistance to these drugs over time (Poveda *et al.*, 2017). Based on our previous finding that the adaptor SH3BP2 was able to regulate *KIT* and MITF expression and viability on mast cells (Ainsua-Enrich *et al.*, 2015), we explored the ability of this protein to regulate these events in GIST. To date, the expression and functional role of SH3BP2 and MITF in GIST was not known. In this work, we characterize that SH3BP2, and the transcription factor MITF, were expressed in primary GIST tumors and in different GIST cell lines harboring different clinically representative primary and secondary mutations. Interestingly, SH3BP2 was not expressed in the sample from a primary GIST WT; however, as GISTs of this kind are very rare tumors and we were only able to analyze a single sample, we cannot conclude that this result is common to other GIST WT and further experiments would be needed.

The silencing of SH3BP2 had a proapoptotic effect on imatinib-sensitive GIST882 and imatinib-resistant GIST48 cell lines, which was concomitant to the downregulation of *KIT* oncogenic protein levels. Interestingly, SH3BP2 silencing also led to a PDGFRA receptor reduction, indicating that SH3BP2 may additionally modulate both tyrosine kinase receptors and may also be a target for *KIT*-negative GISTs. Supporting this notion is the fact that SH3BP2 colocalizes with both receptors in GIST cells. In this context, SH3BP2 may act as a common adaptor in both receptor signaling

pathways. We searched for a direct interaction of SH3BP2 and *KIT* using three hybrid system technologies described elsewhere (Sayos *et al.*, 2001), but we were unable to see any direct association (Ainsua-Enrich *et al.*, 2015). Thus, the binding of SH3BP2 to the receptors could be mediated by a common protein partner of these molecules such as Grb2, PLC $\gamma$ , or PI3K.

Loss of the *KIT* and PDGFRA oncoproteins has a strong apoptotic effect on GIST cells, as is observed after knocking down these receptors with siRNA or treatment with HSP90 inhibitors (Bauer *et al.*, 2006; Liu *et al.*, 2007). It is therefore likely that the downregulation of *KIT*/PDGFRA makes a substantial contribution to the effect of SH3BP2 silencing in GIST cells.

Microphthalmia-associated transcription factor has been reported to regulate *KIT* expression and is critical for mast cells differentiation (Tsujiyama *et al.*, 1996) (Qi *et al.*, 2013). It has also been described as an oncogene in melanoma (Garraway *et al.*, 2005) and now, for first time, we show its expression in GISTs and its ability to regulate tumor cell viability. The role of MITF in the regulation of PDGFRA transcription has not been previously described, but using PATCH software, which uses the positional weight matrices from TRANSFAC database (Wingender *et al.*, 2000), we found three CATGTG sites—putative MITF binding sites—in the PDGFRA promoter at position  $-1840$ ,  $-1464$ , and  $-1307$  (with regard to the TSS described in (Kawagishi *et al.*, 1995)). Therefore, it may be the case that MITF modulates PDGFRA transcription, but this possibility needs to be further examined. It has been reported that MITF regulates proliferation and apoptosis through CDK2 and BCL2 in melanoma cells (Du *et al.*, 2004; McGill *et al.*, 2002). It is conceivable that MITF downregulation by SH3BP2 silencing may also affect GIST cell survival; interestingly, MITF reconstitution in SH3BP2-silenced cells significantly restored cell survival. Our results identify SH3BP2 as an important mediator of cell survival and a regulator of *KIT* expression at protein and mRNA level through the control of MITF expression in GIST cells. However, we cannot rule out the possibility that other factors may be involved in SH3BP2-dependent *KIT* expression.

It has been shown that the proteasome inhibitor bortezomib causes a transcriptional downregulation of *KIT* (Bauer *et al.*, 2010) and MITF expression in mast cells (Lee *et al.*, 2011). Interestingly, we found that bortezomib also induces SH3BP2 and MITF downregulation in GIST882 cells. As bortezomib leads to a wide-ranging effects on cellular function beyond *KIT* transcription (Bauer *et al.*, 2010), the interpretation of these data, suggesting common regulatory pathways of these proteins, requires caution. Agreeing with the

existence of common and reciprocal pathways, it has been reported that there is an inverse regulation between MITF and KIT, through selective miRNA expression. MiR-539 and miR-381 have been shown to be down-regulated by KIT signaling, and they repressed MITF expression through conserved miRNA binding sites in the MITF 3'-untranslated region in mast cells (Lee *et al.*, 2011). KIT signaling through PI3K and PLC gamma is attenuated after SH3BP2 silencing in GIST, so it is conceivable that selective miRNA expression dependent on KIT signaling will be altered as well. Further experiment will be needed to explore miRNA signature in SH3BP2-silencing context. As the mRNA levels of MITF are not decreased by SH3BP2 silencing, it is likely that SH3BP2 may also act by regulating miRNA, thus affecting the expression of MITF or other molecules involved in KIT/PDGFR $\alpha$ -dependent events. The fact that MITF mRNA levels are significantly higher in GIST48 after SH3BP2 silencing may be attributed to a compensatory cell mechanism. On the other hand, the transcription factor ETV1 has been reported to be required for GIST cell growth and development of an aggressive phenotype (Chi *et al.*, 2010), and its expression correlates with KIT expression (Zhang *et al.*, 2014). Indeed, preliminary data from our group show that SH3BP2 silencing reduces ETV1 as well. Interestingly, imatinib treatment reduces SH3BP2 and MITF expression suggesting a positive feed-forward loop that would support the critical oncogenic signaling pathway in these cells. The axis KIT-SH3BP2-MITF was shown to be key for mast cell survival (Ainsua-Enrich *et al.*, 2015).

Our results show that SH3BP2 silencing affects not only cell survival but also cell motility. Interestingly, GIST48B cells, which lack KIT expression, migrate in a similar way to GIST48 cells. As we have shown, GIST48B cells upregulate PDGFR $\alpha$  expression in comparison with GIST48 cells, and this phenomenon may compensate for the lack of KIT; accordingly, PDGFR $\alpha$  appears phosphorylated and presumably activated. SH3BP2 silencing leads to a decreased PDGFR $\alpha$  expression in GIST48B and to a subsequent reduction in cell migration and an increase in cell apoptosis.

Finally, we analyzed the ability of SH3BP2 to inhibit tumor growth *in vivo*. We first performed xenograft experiments with SH3BP2-silenced GIST882 cells which showed a significant delay in GIST subcutaneous tumor grafting and a reduction in final tumor volume compared to nonsilenced cells. After unsuccessful attempts to perform GIST48-xenograft models, we used GIST430/654 as an imatinib-resistant GIST model. Using this cell line, the deleterious effect of SH3BP2 silencing on tumor formation was more

evident than in the GIST882 model, probably due to more efficient SH3BP2 silencing. However, in both cases, our results showed a significant impairment in the ability of SH3BP2-silenced cells to form tumors.

Because most imatinib-resistant GISTs develop secondary mutations within the KIT or PDGFR $\alpha$  kinase domains, novel therapeutic approaches that do not directly target these kinases are particularly important. The example of HSP90 inhibitors, or bortezomib, which both lead to a loss of KIT oncoprotein expression in GISTs, supports this notion (Bauer *et al.*, 2006, 2010). In this respect, we have shown that SH3BP2 regulates KIT and PDGFR $\alpha$  expression, induces apoptosis, and impairs migration in GIST cells. Our results provide compelling information on SH3BP2 as a new selective target against GIST cells harboring various resistance mutations. The use of KIT/PDGFR $\alpha$ -targeted nanoparticles that encapsulate SH3BP2 siRNA, alone or in combination with tyrosine kinase inhibitors, may constitute a novel therapeutic tool for the treatment of imatinib-resistant GISTs. Moreover, the use of MITF inhibitors could be useful against GIST development and progression. Finally, both SH3BP2 and MITF may also be useful targets, in other malignancies in which KIT is the driven molecule, such as acute myeloid leukemia (AML), mastocytosis, or certain cases of melanoma.

## 5. Conclusion

Our data show that SH3BP2 is a key molecule involved in the modulation of KIT/PDGFR $\alpha$  expression, cell migration, and viability, both *in vitro* and *in vivo* in GIST. This suggests that SH3BP2 or SH3BP2 partners may be potential targets for GIST treatment and other malignancies in which KIT/PDGFR $\alpha$  are mutated.

## Acknowledgements

We thanks to Rocío Nieto Raya for her assistance with experiments. This study has been funded by Instituto de Salud Carlos III (Spain) through the project PI12/00332 and SAF2015-68124-R (Ministry for Economy and Competitiveness, Spain) co-funded by European Regional Development Fund/European Social Fund 'Investing in your future'. It has been partially funded by grants of the Spanish Ministry for Economy and Competitiveness and European Regional Development Fund (ERDF) (PI12/03103, PI12/01095, PI16/00540, and AC15/00066) and Asociación Española contra el Cáncer (AECC GCA15152966ARAN) to Diego Arango and by Instituto de Salud Carlos III Grant No. PI16/01371 to



César Serrano. We are indebted to the service of advanced optical microscopy of the CCIT (University of Barcelona) for its technical help.

## Author contributions

ESC, EAE, and MM conceived the experiments and wrote the manuscript. ESC, EAE, ANF, PR, and AGV performed the experiments. SB and IM provided technical support. JA, DA, JS, and CS provided reagents and technical support and MM secured funding. All authors reviewed the manuscript.

## References

- Ainsua-Enrich E, Alvarez-Errico D, Gilfillan AM, Picado C, Sayos J, Rivera J and Martin M (2012) The adaptor 3BP2 is required for early and late events in FcεpsilonRI signaling in human mast cells. *J Immunol* **189**, 2727–2734.
- Ainsua-Enrich E, Serrano-Candelas E, Alvarez-Errico D, Picado C, Sayos J, Rivera J and Martin M (2015) The adaptor 3BP2 is required for KIT receptor expression and human mast cell survival. *J Immunol* **194**, 4309–4318.
- Alvarez-Errico D, Oliver-Vila I, Ainsua-Enrich E, Gilfillan AM, Picado C, Sayos J and Martin M (2011) CD84 negatively regulates IgE high-affinity receptor signaling in human mast cells. *J Immunol* **187**, 5577–5586.
- Bauer S, Duensing A, Demetri GD and Fletcher JA (2007) KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. *Oncogene* **26**, 7560–7568.
- Bauer S, Parry JA, Muhlenberg T, Brown MF, Seneviratne D, Chatterjee P, Chin A, Rubin BP, Kuan SF, Fletcher JA *et al.* (2010) Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells. *Can Res* **70**, 150–159.
- Bauer S, Yu LK, Demetri GD and Fletcher JA (2006) Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. *Can Res* **66**, 9153–9161.
- Chan PM, Ilangumaran S, La Rose J, Chakrabarty A and Rottapel R (2003) Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region. *Mol Cell Biol* **23**, 3067–3078.
- Chen G, Dimitriou I, Milne L, Lang KS, Lang PA, Fine N, Ohashi PS, Kubes P and Rottapel R (2012) The 3BP2 adapter protein is required for chemoattractant-mediated neutrophil activation. *J Immunol* **189**, 2138–2150.
- Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, Raymond AK, Prieto VG, Oyedeji CO, Hunt KK *et al.* (2004) A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. *Can Res* **64**, 5913–5919.
- Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, Fletcher JA, Dewell S, Maki RG, Zheng D *et al.* (2010) ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. *Nature* **467**, 849–853.
- Deckert M, Tartare-Deckert S, Hernandez J, Rottapel R and Altman A (1998) Adaptor function for the Syk kinases-interacting protein 3BP2 in IL-2 gene activation. *Immunity* **9**, 595–605.
- Du J, Widlund HR, Horstmann MA, Ramaswamy S, Ross K, Huber WE, Nishimura EK, Golub TR and Fisher DE (2004) Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. *Cancer Cell* **6**, 565–576.
- Duensing A, Medeiros F, McConarty B, Joseph NE, Panigrahy D, Singer S, Fletcher CD, Demetri GD and Fletcher JA (2004) Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). *Oncogene* **23**, 3999–4006.
- Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O’Leary TJ, Remotti H, Rubin BP *et al.* (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. *Hum Pathol* **33**, 459–465.
- Foucault I, Le Bras S, Charvet C, Moon C, Altman A and Deckert M (2005) The adaptor protein 3BP2 associates with VAV guanine nucleotide exchange factors to regulate NFAT activation by the B-cell antigen receptor. *Blood* **105**, 1106–1113.
- Garner AP, Gozgit JM, Anjum R, Vodala S, Schrock A, Zhou T, Serrano C, Eilers G, Zhu M, Ketzer J *et al.* (2014) Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. *Clin Cancer Res* **20**, 5745–5755.
- Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhi R, Milner DA, Granter SR, Du J *et al.* (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. *Nature* **436**, 117–122.
- Gasparotto D, Rossi S, Bearzi I, Doglioni C, Marzotto A, Hornick JL, Grizzo A, Sartor C, Mandolesi A, Sciort R *et al.* (2008) Multiple primary sporadic gastrointestinal stromal tumors in the adult: an underestimated entity. *Clin Cancer Res* **14**, 5715–5721.
- Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ *et al.* (2003a) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. *J Clin Oncol* **21**, 4342–4349.



- Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A *et al.* (2003b) PDGFRA activating mutations in gastrointestinal stromal tumors. *Science* **299**, 708–710.
- Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y and Kitamura Y (2003) Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. *Gastroenterology* **125**, 660–667.
- Jevremovic D, Billadeau DD, Schoon RA, Dick CJ and Leibson PJ (2001) Regulation of NK cell-mediated cytotoxicity by the adaptor protein 3BP2. *J Immunol* **166**, 7219–7228.
- Kang YK, Ryu MH, Yoo C, Ryoo BY, Kim HJ, Lee JJ, Nam BH, Ramaiya N, Jagannathan J and Demetri GD (2013) Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. *Lancet Oncol* **14**, 1175–1182.
- Kawagishi J, Kumabe T, Yoshimoto T and Yamamoto T (1995) Structure, organization, and transcription units of the human alpha-platelet-derived growth factor receptor gene, PDGFRA. *Genomics* **30**, 224–232.
- Kinoshita K, Hirota S, Isozaki K, Ohashi A, Nishida T, Kitamura Y, Shinomura Y and Matsuzawa Y (2004) Absence of c-kit gene mutations in gastrointestinal stromal tumours from neurofibromatosis type 1 patients. *J Pathol* **202**, 80–85.
- Lasota J and Miettinen M (2008) Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. *Histopathology* **53**, 245–266.
- Lee YN, Brandal S, Noel P, Wentzel E, Mendell JT, McDevitt MA, Kapur R, Carter M, Metcalfe DD and Takemoto CM (2011) KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation. *Blood* **117**, 3629–3640.
- Liu Y, Tseng M, Perdreau SA, Rossi F, Antonescu C, Besmer P, Fletcher JA, Duensing S and Duensing A (2007) Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate. *Can Res* **67**, 2685–2692.
- Lyseng-Williamson K, Jarvis B (2001) Imatinib. *Drugs* **61**, 1765–1774; discussion 1775–1766.
- Marino MP, Luce MJ and Reiser J (2003) Small- to large-scale production of lentivirus vectors. *Methods Mol Biol* **229**, 43–55.
- McGill GG, Horstmann M, Widlund HR, Du J, Motyckova G, Nishimura EK, Lin YL, Ramaswamy S, Avery W, Ding HF *et al.* (2002) Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. *Cell* **109**, 707–718.
- McLean SR, Gana-Weisz M, Hartzoulakis B, Frow R, Whelan J, Selwood D and Boshoff C (2005) Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala. *Mol Cancer Ther* **4**, 2008–2015.
- Metcalfe DD and Mekori YA (2017) Pathogenesis and pathology of mastocytosis. *Ann Rev Pathol* **12**, 487–514.
- Miettinen M, Sobin LH and Lasota J (2005) Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. *Am J Surg Pathol* **29**, 52–68.
- Muhlenberg T, Zhang Y, Wagner AJ, Grabellus F, Bradner J, Taeger G, Lang H, Taguchi T, Schuler M, Fletcher JA *et al.* (2009) Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. *Can Res* **69**, 6941–6950.
- Poveda A, Garcia Del Muro X, Lopez-Guerrero JA, Cubedo R, Martinez V, Romero I, Serrano C, Valverde C and Martin-Broto J (2017) GEIS guidelines for gastrointestinal sarcomas (GIST). *Cancer Treat Rev* **55**, 107–119.
- Qi X, Hong J, Chaves L, Zhuang Y, Chen Y, Wang D, Chabon J, Graham B, Ohmori K, Li Y *et al.* (2013) Antagonistic regulation by the transcription factors C/EBPalpha and MITF specifies basophil and mast cell fates. *Immunity* **39**, 97–110.
- Reichardt P, Hogendoorn PC, Tamborini E, Loda M, Gronchi A, Poveda A and Schoffski P (2009) Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues. *Semin Oncol* **36**, 290–301.
- Ren R, Mayer BJ, Cicchetti P and Baltimore D (1993) Identification of a ten-amino acid proline-rich SH3 binding site. *Science* **259**, 1157–1161.
- Rosnet O, Marchetto S, deLapeyriere O and Birnbaum D (1991) Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. *Oncogene* **6**, 1641–1650.
- Rubin BP, Heinrich MC and Corless CL (2007) Gastrointestinal stromal tumour. *Lancet* **369**, 1731–1741.
- Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA *et al.* (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. *Can Res* **61**, 8118–8121.
- Sayos J, Martin M, Chen A, Simarro M, Howie D, Morra M, Engel P and Terhorst C (2001) Cell surface receptors Ly-9 and CD84 recruit the X-linked lymphoproliferative disease gene product SAP. *Blood* **97**, 3867–3874.

- Serrano C, George S, Valverde C, Olivares D, Garcia-Valverde A, Suarez C, Morales-Barrera R and Carles J (2017) Novel insights into the treatment of imatinib-resistant gastrointestinal stromal tumors. *Target Oncol* **12**, 277–288.
- Smyth T, Van Looy T, Curry JE, Rodriguez-Lopez AM, Wozniak A, Zhu M, Donsky R, Morgan JG, Mayeda M, Fletcher JA *et al.* (2012) The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models. *Mol Cancer Ther* **11**, 1799–1808.
- Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A, Bertulli R, Colecchia M, Casali PG, Pierotti MA *et al.* (2004) A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. *Gastroenterology* **127**, 294–299.
- Tornillo L (2014) Gastrointestinal stromal tumor – an evolving concept. *Front Med* **1**, 43.
- Tsujimura T, Morii E, Nozaki M, Hashimoto K, Moriyama Y, Takebayashi K, Kondo T, Kanakura Y and Kitamura Y (1996) Involvement of transcription factor encoded by the *mi* locus in the expression of *c-kit* receptor tyrosine kinase in cultured mast cells of mice. *Blood* **88**, 1225–1233.
- Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA and Demetri GD (2001) STI571 inactivation of the gastrointestinal stromal tumor *c-KIT* oncoprotein: biological and clinical implications. *Oncogene* **20**, 5054–5058.
- Wingender E, Chen X, Hehl R, Karas H, Liebich I, Matys V, Meinhardt T, Pruss M, Reuter I and Schacherer F (2000) TRANSFAC: an integrated system for gene expression regulation. *Nucleic Acids Res* **28**, 316–319.
- Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U and Ullrich A (1987) Human proto-oncogene *c-kit*: a new cell surface receptor tyrosine kinase for an unidentified ligand. *EMBO J* **6**, 3341–3351.
- Zhang Y, Gu ML, Zhou XX, Ma H, Yao HP and Ji F (2014) Altered expression of ETV1 and its contribution to tumorigenic phenotypes in gastrointestinal stromal tumors. *Oncol Rep* **32**, 927–934.

## Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article:

**Fig. S1.** Phosphorylation status of KIT and PDGFRA in GIST882, GIST48 and GIST48B cells.

**Fig. S2.** SH3BP2 colocalizes with KIT and PDGFRA in GIST cells.

**Fig. S3.** PLC gamma and AKT phosphorylation are affected in SH3BP2-silenced GIST882 and GIST48 cells.

**Fig. S4.** Evaluation of reconstitution efficiency of GIST48 SH3BP2 silenced cells.

**Fig. S5.** Imatinib and bortezomib treatment of GIST882 reduces SH3BP2 and MITF levels.

**Fig. S6.** SH3BP2 and MITF are expressed in GIST cell lines with different mutations.